drugset

drugset / Trial / NCT02687490

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

NCT02687490 ↗

Phase 2 Completed 81 enrolled Fudan University

NaSingle-groupOpen-labelTreatment

Summary

Abraxane in patients with visceral metastases dominant metastatic breast cancer

Timeline

Start: 2017-02-24
Primary completion: 2020-12-01
Completion: 2020-12-15

Publications

Xie Y, Gong C, Zhang J, Wang L, Cao J, Tao Z, Li T, Zhao Y, Li Y, Hu S, Wang B, Hu X. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. BMC Cancer. 2021 Nov 2;21(1):1174. doi: 10.1186/s12885-021-08921-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nab-paclitaxel	Small molecule	125 mg/m2	—

Indications